HC Wainwright & Co. Assumes NewAmsterdam Pharma Co at Buy, Announces Price Target of $52
Benzinga Newsdesk 1 year ago
NewsPrice TargetInitiationAnalyst Ratings
HC Wainwright & Co. analyst Joseph Pantginis assumes NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy rating and announces Price Target of $52.
HC Wainwright & Co. analyst Joseph Pantginis assumes NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy rating and announces Price Target of $52.